Onkológia S2/2024

Benefits of modern agents in the treatment of multiple myeloma – our experiences

Purpose: With the arrival of immunomodulators (IMiDs) and proteasome inhibitors (PIs), treatment outcomes have significantly improved, with many patients living with their disease for over 10 years. Case: This case report is a case of a patient who had been sent to our outpatient clinic with multiple bone lesions in an immobile state and who has been in excellent physical and mental condition thanks to treatment with modern agents for 10 years. Conclusion: The case described has shown the benefits of modern agents in the treatment of multiple myeloma, allowing long-term disease control and significant prolongation of survival. Concurrently, clinical trial observations on the suitability of the use of pomalidomide immediately after lenalidomide have been confirmed.

Keywords: multiple myeloma, long-term disease control, pomalidomide